Plus Therapeutics to Present Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

On July 28, 2022 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, reported it will present data from two ongoing clinical trials for recurrent glioblastoma and leptomeningeal metastases at the 2022 Annual Conference on CNS Clinical Trials and Brain Metastases, co-sponsored by the Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), being held August 12-13, 2022 in Toronto, Canada (Press release, Cytori Therapeutics, JUL 28, 2022, View Source [SID1234617071]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of oral presentation:

Title LOCL-04: Safety and Feasibility of Rhenium-186 Nanoliposome (186RNL) in Leptomeningeal Metastases [LM] Phase 1/2a dose
Date August 12, 2022 from 2:15 – 4:00 p.m. ET
Session Oral abstract, Session 3: Enhancing Local and Compartmental Therapies
Presenter Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECT-LM clinical trial
Details of poster presentation:

Title LOCL-08: Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT Phase 1 Trial
Date August 12, 2022 from 6:20 – 8:20 p.m. ET
Session Poster display, Poster and Networking Reception
Presenter Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECT-GBM clinical trial
Electronic posters will be made available online at the start of the conference in addition to the in-person poster reception on Friday evening, August 12, 2022. For more information visit View Source

A copy of the posters will also be available under the Presentations tab of the Investors section of the Company’s website at the time of the presentations at View Source

Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022

On July 28, 2022 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that the Company will release its second quarter 2022 financial results on Thursday, August 4, 2022, after the close of U.S. markets (Press release, Curis, JUL 28, 2022, View Source,-2022 [SID1234617070]). Management will host a conference call on the same day at 4:30 pm ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 pm ET. The conference call can also be accessed on the Curis website at www.curis.com in the ‘Investors’ section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

On July 28, 2022 Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, reported that it has entered into an exclusive license agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093) to develop and commercialize EO-3021 (SYSA1801), a differentiated, clinical stage antibody drug conjugate (ADC) targeting Claudin18.2, in all global territories outside Greater China (mainland China, Hong Kong, Macau and Taiwan) (Press release, Elevation Oncology, JUL 28, 2022, View Source [SID1234617069]). SYSA1801 is currently being evaluated by CSPC in a Phase 1, dose-escalation clinical trial in China. Elevation Oncology expects to initiate a Phase 1 clinical trial evaluating EO-3021 in the U.S. in 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This licensing transaction represents successful, continued execution of our business development strategy and expands our clinical-stage pipeline," said Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology. "We look forward to unlocking the potential of EO-3021 alongside our partner CSPC as we continue to build an industry-leading precision oncology company. EO-3021 is an exciting, differentiated ADC that has significant potential for the treatment of patients with solid tumors that express Claudin18.2, including those with genomically defined cancers. This transaction is a significant milestone for Elevation Oncology which further diversifies our company, expands our commercial potential and allows us to leverage our existing expertise in genomically defined cancers."

Claudin18.2 is a protein expressed across several types of solid tumors including many gastrointestinal cancers such as gastric, gastroesophageal junction (GEJ), and pancreatic cancer. EO-3021 is an ADC containing monomethyl auristatin E (MMAE) payload, a potent anti-mitotic agent. MMAE has been clinically validated as an effective anti-tumor payload and is the cytotoxic component of four U.S. Food and Drug Administration-approved ADCs.

"Claudin18.2 is a clinically validated oncology target that has significant potential in multiple gastrointestinal cancers and several other solid tumors, and could be best addressed by utilizing a weaponized antibody like EO-3021," said David Dornan, PhD, Chief Scientific Officer of Elevation Oncology. "High Claudin18.2 expression is associated particularly with gastrointestinal cancers, but can also frequently be found in lung, breast and liver cancer, representing an attractive commercial market opportunity. The targeting of Claudin18.2 with EO-3021 could have a transformative role in addressing the unmet medical need in patients whose tumors express Claudin18.2."

Under the terms of the agreement, Elevation Oncology will develop and commercialize EO-3021 in all global territories outside of Greater China. In exchange, CSPC will receive a one-time, upfront payment of $27 million. CSPC will also be eligible to receive up to $148 million in potential development and regulatory milestone payments and up to $1.0 billion in potential commercial milestone payments plus royalties on net sales.

"This agreement with Elevation Oncology brings our innovative pipeline overseas with the potential to help patients battling cancer. We are delighted to partner with Elevation Oncology to realize the full global potential for SYSA1801 (EO-3021) in meeting the unmet medical needs in pancreatic and gastric cancer, as well as other types of cancers," said Zhang Cuilong, Chief Executive Officer of CSPC. "Recognizing the value that Elevation Oncology has created in building an industry-leading operational platform for enrolling clinical trials in genomically defined patient populations, this partnership gives us confidence in the potential worldwide development of this program targeting Claudin18.2."

Conference Call and Webcast Information

Elevation Oncology will host an investor conference call and webcast today, Thursday, July 28, 2022, at 5:00 p.m. ET to discuss the licensing transaction with CSPC. To access the live call, please dial 1-877-870-4263 (local) or 1-412-317-0790 (international) at least 10 minutes prior to the start time of the call and ask to be joined into the Elevation Oncology investor call. The live, listen-only webcast of the conference call can be accessed by visiting the "Events" page within the "Investors" section of Elevation Oncology’s website at www.elevationoncology.com. An archived replay of the webcast will be available on Elevation Oncology’s website approximately two hours after the event.

About EO-3021

EO-3021 (also known as SYSA1801) is a differentiated, clinical stage antibody drug conjugate that targets Claudin18.2. Claudins are a family of proteins acting to maintain the tight junction that controls the interchange of molecules between cells and are mainly found in gastric, pancreatic, and lung tissues.1 Claudin18.2 is a specific subtype that is expressed in only cancer cells of the gastric epithelia.1 When the gastric epithelial cells become malignant, the tight junctions become disrupted, exposing the Claudin18.2 epitopes and allowing them to be targeted by anti-cancer agents.1 An Investigational New Drug application for EO-3021 has been cleared with the U.S. Food and Drug Administration.

Cellectis to Report Second Quarter 2022 Financial Results

On July 28, 2022 Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported that it will report financial results for the second quarter ended June 30th, 2022, on Thursday, August 4th, 2022, after the close of the US market (Press release, Cellectis, JUL 28, 2022, View Source [SID1234617068]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The announcement will be followed by a conference call and webcast on Friday, August 5th, 2022, at 8:00 AM EDT / 2:00 PM CET. The call will include the Company’s second quarter results and an update on business activities.

BIO-TECHNE ANNOUNCES LICENSING AGREEMENT AND PARTNERSHIP WITH UNIVERSITY OF DUNDEE

On July 28, 2022 Bio-Techne Corporation (NASDAQ: TECH) reported the signing of an exclusive licensing agreement to commercialize The University of Dundee’s BromoTAG system and fund the recruitment of postdoctoral researchers at the University’s Centre for Targeted Protein Degradation (CeTPD) (Press release, Bio-Techne, JUL 28, 2022, View Source [SID1234617067]). CeTPD researchers will create new chemical tools that will be commercialized by Tocris, a Bio-Techne brand, for use by the biopharmaceutical research community.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BromoTAG enables scientists to determine which individual proteins possess the greatest potential as a target for new therapeutic agents. Using genome-editing technologies, BromoTAG pins a small biological tag to a target protein and labels it for subsequent modifications, for example cellular degradation, allowing researchers to evaluate its functional role and impact on disease development. BromoTAG was developed by Conner Craigon and Adam Bond, PhD students at CeTPD and is a powerful chemical biology tool, enabling the rapid and selective removal of any individual protein. It has been shown to degrade the tagged protein at low concentration, within minutes, and reversibly. Critically, it degrades only the individual target protein and prevents any off-target effects.

The University of Dundee is a leader in Targeted Protein Degradation (TPD), a field of research that is revolutionising drug discovery. This approach is making the treatment of diseases previously thought to be undruggable a reality. Dundee researchers and teams led by CeTPD Director, Professor Alessio Ciulli, have previously revealed fundamental insights into the working of the degrader molecules that they have designed and that are used across the globe. Professor Ciulli is a pioneer in protein degraders research, while Tocris has strong know-how and expertise in organic chemistry. Over the past five years, Tocris has been working with Professor Ciulli to commercialize various chemical tools such as inhibitors and degraders developed in his lab.

"We are excited about TPD, both as an enabling technology for life science research, as well as for its potential to deliver new therapeutics in the clinic," said Will Geist, Bio-Techne’s Protein Sciences Segment President. "Bio-Techne has built a leading portfolio of tools and technologies to support scientists through every stage of their TPD research, and we are delighted to offer BromoTAG to researchers through this exclusive license. We have a long-standing relationship with the University of Dundee to commercialize exciting and useful technologies and look forward to expanding this relationship through our support of post-doctoral research."

Professor Ciulli said, "We are delighted to announce the successful commercialization of a recent CeTPD discovery, and for continued collaborative work between Dundee and Tocris. We will jointly work to develop the next-generation BromoTAG for a variety of applications. The licensing deal deepens the relationship between the University and Bio-Techne. These developments cement the importance of our research to the field of targeted protein degradation."